QLGN - Qualigen Therapeutics, Inc. Stock Price, Fair Value and News

0.29USD-0.02 (-6.45%)Delayed as of 16 May 2024, 10:55 am ET

Market Summary

USD0.29-0.02

Delayedas of 16 May 2024, 10:55 am

-6.45%

QLGN Stock Price

View Fullscreen

QLGN RSI Chart

QLGN Valuation

Market Cap

2.0M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

0.46

EV/EBITDA

-0.2

Price/Free Cashflow

-0.19

QLGN Price/Sales (Trailing)

QLGN Profitability

EBT Margin

-247.15%

Return on Equity

637.83%

Return on Assets

-659.89%

Free Cashflow Yield

-527%

QLGN Fundamentals

QLGN Revenue

Revenue (TTM)

5.3M

QLGN Earnings

Earnings (TTM)

-13.4M

Earnings Growth (Yr)

65.67%

Earnings Growth (Qtr)

42.97%

Breaking Down QLGN Revenue

52 Week Range

0.291.26

(Low)(High)

Last 7 days

7.1%

Last 30 days

-6.2%

Last 90 days

-36.2%

Trailing 12 Months

-69.7%

How does QLGN drawdown profile look like?

QLGN Financial Health

Current Ratio

0.28

Debt/Equity

-0.62

Debt/Cashflow

-7.93

QLGN Investor Care

Shares Dilution (1Y)

24.84%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	5.3M	0	0
2022	4.5M	4.8M	0	0
2021	4.7M	5.0M	5.3M	5.7M
2020	5.5M	4.9M	4.5M	4.2M
2019	172.2K	1.7M	2.8M	4.2M
2018	58.3K	73.7K	86.8K	126.8K
2017	48.3K	37.9K	28.8K	40.2K
2016	59.2K	73.8K	68.2K	60.9K
2015	0	0	0	40.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Qualigen Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 22, 2022	poirier michael s.	bought	17,100	0.57	30,000	chairman and ceo
Jun 14, 2022	broidrick amy s.	bought	18,600	0.62	30,000	president/cso
Aug 19, 2021	kruger kurt h	bought	9,800	1.225	8,000	-
Apr 26, 2021	broidrick amy s.	bought	9,135	2.03	4,500	evp, chief strategy officer
Apr 20, 2021	poirier michael s.	bought	19,809	1.8	11,005	chairman, ceo & president
Apr 16, 2021	lotz christopher l.	bought	5,022	1.86	2,700	vice president of finance, cfo
Dec 29, 2020	kruger kurt h	bought	11,740	2.935	4,000	-
Nov 23, 2020	kruger kurt h	bought	15,925	3.462	4,600	-
Nov 20, 2020	kruger kurt h	bought	4,968	3.549	1,400	-
May 22, 2020	poirier michael s.	acquired	-	-	169,192	chairman, president & ceo.

Which funds bought or sold QLGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-1,749	4,263	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-98.8	-455	4.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	15.72	-458	2,435	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	64.4	3,171	22,299	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-1,789	4,767	-%
May 14, 2024	ICA Group Wealth Management, LLC	sold off	-100	-135	-	-%
May 13, 2024	FMR LLC	sold off	-100	-1.00	-	-%
May 13, 2024	XTX Topco Ltd	new	-	4,233	4,233	-%
May 13, 2024	UBS Group AG	sold off	-100	-56.00	-	-%

Are Funds Buying or Selling QLGN?

Are funds buying QLGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own QLGN

No. of Funds

Unveiling Qualigen Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 27, 2022	alpha capital anstalt	9.99%	3,525,042	SC 13G/A
Jan 05, 2022	sabby management, llc	12.%	0	SC 13G/A
Dec 06, 2021	sabby management, llc	5.55%	1,960,000	SC 13G
Jun 01, 2020	greenblock capital, llc	6.5%	811,431	SC 13G
Jun 01, 2020	greenblock capital, llc	6.5%	811,431	SC 13G
Jun 01, 2020	sekisui diagnostics, llc	-	1,980,233	SC 13G
Jun 01, 2020	sekisui diagnostics, llc	-	1,980,233	SC 13G
May 28, 2020	alpha capital anstalt	9.9%	1,240,088	SC 13G
Feb 14, 2020	alyeska investment group, l.p.	4.2%	425,000	SC 13G/A
Jan 29, 2020	step michael d	0.7%	128,757	SC 13G/A

Recent SEC filings of Qualigen Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	NT 10-Q	NT 10-Q
May 06, 2024	S-1/A	Initial Public Offering
May 03, 2024	424B3	Prospectus Filed
May 02, 2024	EFFECT	EFFECT
May 01, 2024	POS AM	POS AM
Apr 16, 2024	8-K	Current Report
Apr 08, 2024	10-K	Annual Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 28, 2024	8-K	Current Report
Feb 27, 2024	8-K	Current Report

Peers (Alternatives to Qualigen Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.5B	6.8B	24.29%	3.18%	-8.29	7.22	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.16%	-22.78%	-56.17	9.31	75.20%	68.82%
BMRN	15.3B	2.5B	-12.17%	-12.66%	74.28	6.17	13.74%	186.89%
INCY	12.8B	3.8B	6.79%	-11.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	16.38%	112.85%	-10.26	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.64%	-52.21%	-12.19	9.71	394.93%	39.61%
AXSM	3.6B	251.0M	11.42%	-1.40%	-12.17	14.37	73.58%	-86.73%
ARWR	3.1B	240.7M	4.29%	-33.48%	-6.61	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-10.48%	-30.90%	-1.5K	3.07	56.43%	98.83%
SMALL-CAP
CPRX	2.0B	411.3M	8.25%	33.17%	30.22	4.78	60.38%	-34.49%
NVAX	1.8B	996.6M	212.62%	68.59%	-4.54	1.81	-26.66%	65.49%
CRBP	472.0M	881.7K	3.39%	323.08%	-13.98	481.06	-77.61%	33.36%
INO	339.4M	4.9M	19.20%	55.95%	-2.72	69.75	-54.97%	48.23%
IBIO	16.2M	2.1M	-2.59%	102.15%	-0.7	7.61	-13.45%	69.54%

Qualigen Therapeutics, Inc. News

Latest updates

Qualigen Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q2	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	13.7%	1,627,031	1,430,534	722,029	1,481,229	1,155,065	1,117,935	1,899,496	1,107,780	837,714	904,067	1,400,000	1,389,250	1,201,127	1,510,835	71,291	61,870	17,237	21,756	25,972	21,865	4,083
Operating Expenses	-7.1%	5,178,158	5,571,864	5,730,667	6,128,675	5,962,975	8,512,733	7,712,378	6,716,708	4,555,054	3,473,725	2,240,351	2,540,171	1,490,700	2,036,257	4,777,057	7,580,800	4,663,499	3,606,408	2,038,662	-	-
S&GA Expenses	0.2%	2,665,849	2,660,857	2,898,751	3,142,603	2,756,323	2,952,100	2,873,939	2,461,065	2,664,658	1,979,614	918,379	2,945,659	202,679	269,017	1,153,577	1,467,489	1,144,750	1,686,903	1,125,891	-	-
R&D Expenses	-11.9%	1,326,544	1,506,227	1,864,745	-	2,083,315	4,508,466	3,499,373	-	870,876	597,345	238,059	2,204,259	200,217	147,641	3,574,855	6,079,334	-	-	-	-	-
EBITDA Margin	-29.3%	-4.20	-3.25	-3.76	-3.14	-1.22	-2.32	-5.21	-4.82	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-7923.7%	-377,416	4,824	6,309	5,831	6,801	12,718	17,343	-48,039	-715	-57,364	-90,757	-	65,480	69,985	-	-	-	-	-	-	-
Income Taxes	-802.1%	-38,182	5,438	736	2,854	1,011	605	530	-	2,305	597	-619	-455	1,420	150	185,980	-	-	-	-	-	-
Earnings Before Taxes	14.0%	-3,545,871	-4,122,082	-4,319,051	-4,215,578	-3,036,471	-5,397,472	-5,242,189	7,142,850	-8,110,908	-18,578,308	-873,195	38,903	-354,805	-594,415	-	-	-	-	-	-	-
EBT Margin	-23.7%	-4.05	-3.28	-3.79	-3.16	-1.24	-2.34	-5.22	-4.81	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	15.0%	-3,507,689	-4,127,520	-4,319,787	-4,218,859	-3,037,482	-5,398,077	-5,242,719	7,142,715	-8,113,213	-18,578,905	-872,576	-444,892	-356,225	-594,565	-4,705,766	-6,625,106	-4,646,262	-3,584,652	-2,012,690	-	-
Net Income Margin	-3.2%	-3.39	-3.28	-3.79	-3.17	-1.24	-2.34	-5.22	-4.81	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	23.6%	-3,010,825	-3,941,656	-3,949,625	-2,930,340	-3,042,018	-6,749,486	-2,143,369	-3,529,114	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-52.9%	2,033	4,316	13,150	15,914	19,083	22,959	26,349	18,708	22,836	16,405	19,889	25,736	29,127	20,675	8,679	3,720	2,797	2,900	5,014	8,961	15,320
Current Assets	-66.2%	1,167	3,450	4,863	7,538	10,821	10,395	13,705	16,704	20,796	15,733	19,107	24,916	28,225	17,566	5,678	1,619	2,210	2,730	4,826	8,742	15,277
Cash Equivalents	-80.9%	402	2,100	1,300	4,363	3,166	6,618	9,746	13,611	9,174	12,320	15,232	21,948	23,977	14,466	2,306	153	1,700	1,957	71.00	5,517	7,812
Inventory	-	-	-	1,563	1,481	1,586	1,482	1,310	1,401	1,056	1,178	1,073	886	953	805	640	660	-	-	-	-	-
Net PPE	-	-	-	499	522	26.00	312	330	230	204	209	253	225	247	1,565	1,547	1,448	16.00	17.00	19.00	19.00	20.00
Goodwill	-	-	-	626	626	626	4,896	4,896	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-30.6%	4,137	5,957	9,842	9,714	10,317	7,043	7,879	5,192	6,271	5,558	7,627	9,505	10,832	23,564	21,832	5,648	-	2,837	2,879	4,132	5,934
Current Liabilities	-30.6%	4,137	5,957	8,494	8,244	8,608	4,881	5,646	3,626	4,635	5,427	7,417	9,197	10,430	23,096	21,241	5,339	1,697	2,827	2,838	4,062	5,934
Short Term Borrowings	-	-	-	965	959	951	941	940	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	56.1%	1,299	832	812	558	60.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-2,103	-	3,308	6,200	7,236	15,916	18,470	13,517	16,565	10,667	12,262	16,230	18,295	-	-	5,015	1,100	63.00	2,136	4,829	9,386
Retained Earnings	-2.1%	-116,800	-114,352	-110,695	-107,231	-103,385	-97,012	-93,187	-89,064	-84,744	-78,683	-75,825	-70,520	-66,847	-73,993	-65,880	-47,301	-80,333	-79,888	-77,721	-74,906	-70,200
Additional Paid-In Capital	1.8%	114,656	112,669	112,555	111,887	110,528	108,967	107,558	102,546	101,274	89,501	88,058	86,722	85,115	71,082	52,714	45,162	79,885	76,123	75,228	75,105	71,505
Shares Outstanding	6.1%	5,362	5,052	5,052	5,052	4,211	3,715	3,668	3,529	3,529	2,903	2,851	2,817	2,730	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	1,274	1,331	1,531	3,765	3,996	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	4,571	-	-	-	21,943	-	-	-	57,064	-	-	-	45,357	-	-	-	7,100	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-686.3%	-5,671	967	-3,000	-2,600	-2,190	-3,182	-3,946	-3,881	-2,913	-3,032	-6,703	-2,081	-3,456	-4,516	-2,189	408	-4,908	-2,423	-214	-6,544	-3,202
Share Based Compensation	-	70.00	-	654	252	665	1,410	1,423	1,267	1,431	1,300	1,300	1,262	1,215	1,200	400	8.00	75.00	-	-	146	84.00
Cashflow From Investing	-94.4%	235	4,227	-48.41	-198	-244	-11.26	121	-49.62	-17.01	-9.66	-45.69	-69.00	520	-186	-397	-95.46	1,420	-	-72.82	4,249	-6,968
Cashflow From Financing	-Infinity%	-110	-	-	-	2,903	3.00	1*	4.00	8,149	129	34.00	121	12,448	16,787	4,816	-287	-	-421	233	-	5,487

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

QLGN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
EXPENSES
General and administrative	$ 6,095,607	$ 10,274,600
Research and development	5,209,250	4,486,120
Total expenses	11,304,857	14,760,720
LOSS FROM OPERATIONS	(11,304,857)	(14,760,720)
OTHER EXPENSE (INCOME), NET
Gain on change in fair value of warrant liabilities	(2,035,469)	(907,203)
Interest expense, net	1,524,722	34,397
Loss on voluntary conversion of convertible debt	1,077,287
Loss on debt extinguishment	625,653
Loss on fixed asset disposal	21,747
Other income, net	(38,994)
Total other expense (income), net	1,174,946	(872,806)
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES	(12,479,803)	(13,887,914)
(BENEFIT) PROVISION FOR INCOME TAXES	(4,793)	6,548
NET LOSS FROM CONTINUING OPERATIONS	(12,475,010)	(13,894,462)
DISCONTINUED OPERATIONS
Loss from discontinued operations, net of tax	(683,008)	(7,140,181)
Loss on disposal of discontinued operations, net of tax	(602,232)
LOSS FROM DISCONTINUED OPERATIONS	(1,285,240)	(7,140,181)
Net loss	(13,760,250)	(21,034,643)
Net loss attributable to non-controlling interest from discontinued operations	(343,038)	(2,394,100)
Net loss attributable to Qualigen Therapeutics, Inc.	$ (13,417,212)	$ (18,640,543)
Net loss per common share, basic - continuing operations	$ (2.46)	$ (3.62)
Net loss per common share, diluted - continuing operations	(2.46)	(3.62)
Net loss per common share, basic - discontinued operations	(0.19)	(1.24)
Net loss per common share, diluted - discontinued operations	$ (0.19)	$ (1.24)
Weighted-average number of shares outstanding, basic	5,072,709	3,840,340
Weighted-average number of shares outstanding, diluted	5,072,709	3,840,340
Other comprehensive loss, net of tax
Foreign currency translation adjustment from discontinued operations	$ 119,473	$ 50,721
Other comprehensive loss	(13,640,777)	(20,983,922)
Comprehensive loss attributable to noncontrolling interest from discontinued operations	(304,735)	(2,394,100)
Comprehensive loss attributable to Qualigen Therapeutics, Inc.	$ (13,336,042)	$ (18,589,822)

QLGN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 401,803	$ 3,165,985
Prepaid expenses and other current assets	764,964	1,366,704
Current assets of discontinued operations		6,287,849
Total current assets	1,166,767	10,820,538
Property and equipment, net		26,242
Other assets	866,481
Non-current assets of discontinued operations		8,236,711
Total Assets	2,033,248	19,083,491
Current liabilities
Accounts payable	2,222,983	619,568
Accrued expenses and other current liabilities	560,006	864,559
Warrant liabilities	54,600	788,100
Warrant liabilities - related party		2,834,547
Convertible debt - related party	1,299,216	60,197
Current liabilities of discontinued operations		3,441,198
Total current liabilities	4,136,805	8,608,169
Non-current liabilities of discontinued operations		1,708,732
Total liabilities	4,136,805	10,316,901
Commitments and Contingencies (Note 10)
Qualigen Therapeutics, Inc. stockholders’ equity (deficit):
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	43,262	42,110
Additional paid-in capital	114,655,565	110,528,050
Accumulated other comprehensive income		50,721
Accumulated deficit	(116,802,384)	(103,385,172)
Total Qualigen Therapeutics, Inc. stockholders’ equity (deficit)	(2,103,557)	7,235,709
Noncontrolling interest		1,530,881
Total Stockholders’ Equity (deficit)	(2,103,557)	8,766,590
Total Liabilities & Stockholders’ Equity (Deficit)	$ 2,033,248	$ 19,083,491

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

CEO	Mr. Michael S. Poirier
WEBSITE	qualigeninc.com
INDUSTRY	Biotechnology
EMPLOYEES	31

Qualigen Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Qualigen Therapeutics, Inc.? What does QLGN stand for in stocks?

QLGN is the stock ticker symbol of Qualigen Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Qualigen Therapeutics, Inc. (QLGN)?

As of Wed May 15 2024, market cap of Qualigen Therapeutics, Inc. is 1.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QLGN stock?

You can check QLGN's fair value in chart for subscribers.

What is the fair value of QLGN stock?

You can check QLGN's fair value in chart for subscribers. The fair value of Qualigen Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Qualigen Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QLGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Qualigen Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether QLGN is over valued or under valued. Whether Qualigen Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Qualigen Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QLGN.

What is Qualigen Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, QLGN's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 0.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QLGN PE ratio will change depending on the future growth rate expectations of investors.